共 47 条
[1]
Ravi P(2018)Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies Blood Cancer J 8 26-812
[2]
Kumar SK(2000)Predictive role of interphase cytogenetics for survival of patients with multiple myeloma J Clin Oncol 18 804-639
[3]
Cerhan JR(2016)Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma Leukemia. 30 633-235
[4]
Königsberg R(2015)The t(11;14)(q13;q32) translocation as a poor prognostic parameter for autologous stem cell transplantation in myeloma patients with extramedullary plasmacytoma Clin Lymphoma Myeloma Leuk 15 227-138
[5]
Zojer N(2018)Natural history of t(11;14) multiple myeloma Leukemia. 32 131-837
[6]
Ackermann J(2000)The (11;14)(q13;q32) translocation in multiple myeloma: a morphologic and immunohistochemical study Am J Clin Pathol 113 831-681
[7]
Kaufman GP(1996)Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines Blood. 88 674-2409
[8]
Gertz M(2017)Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma Blood. 30 2401-2400
[9]
Dispenzieri A(2017)Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory multiple myeloma Blood. 130 2392-1944
[10]
Shin HJ(2019)A phase 3 study of venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma [abstract LB2601] Clin Lymphoma Myeloma Leuk 19 e31-1558